The US Food and Drug Administration (FDA) has accepted 鈥� completed new drug application (NDA) submission for suzetrigine, as the company鈥檚 non-opioid-based treatment for acute pain inches closer to market.
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 January 2025, according to a 30 July press release.
Shares in the US company, which has a market cap of $129.7bn, opened 0.9% higher on 31 July.
Formerly known as VX-548, suzetrigine has fast track and breakthrough therapy designations for its use as a treatment for moderate to severe acute pain, meaning the drug has an expedited review process. The agency previously granted a rolling NDA submission to Vertex in April this year.
Suzetrigine is a voltage-gated sodium channel inhibitor, specifically targeting NaV1.8. This channel is expressed in peripheral pain-sensing neurons, known as nociceptors, and plays a role in propagating pain signals.
Vertex states it aims to create a 鈥渘ew class of pain signal inhibitors鈥�, that go beyond the limitations of current therapies 鈥� one of which is the addictive nature of opioids. The over-prescription of opioid pain medication such as oxycontin, along with the widespread availability of synthetic opioids such as fentanyl, has led to epidemics around the world. Opioid overdoses are the leading cause of accidental deaths in the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSuzetrigine demonstrated in two randomised Phase III trials in patients with moderate-to-severe acute pain. The drug led to significant improvements in pain intensity in the 48 hours after patients underwent abdominoplasty (NCT05558410), commonly known as tummy tucks, and bunionectomies (NCT05553366), meaning the studies met their primary endpoints. The pair of trials enrolled 2,193 surgical patients in total.
However, the drug鈥檚 clinical journey was not without a setback. In the same studies, suzetrigine failed to show higher effectiveness compared to the painkiller Vicodin (hydrocodone/acetaminophen), causing the trials to miss their secondary endpoints. Vicodin, manufactured by , is relatively cheap and widely accessible but is opioid-based.
The global pain management market, which includes acute pain, is projected to reach approximately $115bn by 2032, according to GlobalData鈥檚 AI hub.
GlobalData is the parent company of Pharmaceutical Technology.
Suzetrigine is estimated to reach blockbuster status by 2029 and achieve $1.4bn in sales by 2030, according to an analysis by GlobalData鈥檚 Pharma Intelligence Centre.
Vertex鈥檚 executive vice-president, chief regulatory and quality officer Nia Tatsis said: 鈥淭oday鈥檚 FDA filing acceptance for suzetrigine marks a critical milestone toward bringing this new, transformative non-opioid analgesic to the millions of patients suffering from moderate-to-severe acute pain each year in the US.鈥�
Tatsis added that the filing brings Vertex one step closer to 鈥渇illing the gap between medicines with good tolerability but limited efficacy and opioid medicines with therapeutic efficacy but known risks, including addictive potential鈥�.
